Could COX-2 Inhibition With Celecoxib Have Role in Breast Cancer?

Video

This video highlights results of REACT, a phase III multi-center double-blind randomized trial of celecoxib vs placebo in patients with breast cancer.

In this video, R. Charles Coombes, MD, PhD, of Imperial College London, United Kingdom, discusses results of REACT (Randomised European Celecoxib Trial), a phase III multi-center double-blind randomized trial of celecoxib vs placebo in patients with breast cancer.

Coombes presented results of this study (abstract GS3-03) at the 2017 San Antonio Breast Cancer Symposium (SABCS).

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content
Maintenance Tucatinib Combo Yields PFS Extension in Advanced HER2+ Breast Cancer

Maintenance Tucatinib Combo Yields PFS Extension in Advanced HER2+ Breast Cancer

Caroline Seymour
December 11th 2025
Article

“HER2CLIMB-05 has demonstrated that the addition of tucatinib to HP represents an enhanced frontline maintenance therapy option for patients with HER2-positive metastatic breast cancer,” said Erika Hamilton, MD.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Giredestrant’s safety in the lidERA BC trial was consistent with its known profile, with a lower discontinuation rate vs SOC endocrine therapy.

Frontline Giredestrant Displays IDFS Improvement vs SOC ET in ER+/HER2– BC

Roman Fabbricatore
December 10th 2025
Article

Giredestrant’s safety in the lidERA BC trial was consistent with its known profile, with a lower discontinuation rate vs SOC endocrine therapy.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Across different studies, the highest incidence of left ventricular ejection fraction decrease was seen with trastuzumab/pertuzumab plus chemotherapy.

T-DM1 Confers Lower Cardiotoxicity Risk in HER2+ Advanced Breast Cancer

Russ Conroy
December 8th 2025
Article

Across different studies, the highest incidence of left ventricular ejection fraction decrease was seen with trastuzumab/pertuzumab plus chemotherapy.

3 Things You Should Know About ADCs in Early-Stage TNBC and Considerations for Implementation

3 Things You Should Know About ADCs in Early-Stage TNBC and Considerations for Implementation

ONCOLOGY Staff
December 8th 2025
Article

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer and their unique safety profiles.